SIGY's Landmark COVID-19 Study Results Could Lead to Price Gains

Investment and Company Research
Opportunity Research
COMPANY UPDATE

icon Download Report in PDF Or Scroll down to read the complete report below.

SIGYN THERAPEUTICS, INC.

New Study Results May Be Precursor to Major Value Jump for SIGY

Rob Goldman

[email protected]

April 27, 2021

SIGYN THERAPEUTICS, INC. (OTC – SIGY - $1.80)

Industry: Medical Devices

6-12 Mo. Price Target: $9.00

COMPANY SNAPSHOT

Sigyn Therapeutics™ is a development-stage therapeutic technology company targeting a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Cytokine storm syndrome is the hallmark of sepsis, the most common cause of in-hospital deaths. Virus induced cytokine storm is a leading cause of COVID-19 deaths. Other therapeutic opportunities include bacteria induced cytokine storm, acute respiratory distress syndrome and acute forms of liver failure, such as hepatic encephalopathy.

KEY STATISTICS

Price as of 4/26/21 $1.80
52 Wk High - Low $3.50 - $1.00
Est. Shares Outstanding 35.2M
Market Capitalization $63.4M
Average Volume 1,952
Exchange: OTCPK

INVESTMENT HIGHLIGHTS

The Bottom Line: SIGY recently published in vitro study results that serve as an affirmation of SIGY’s approach and broad capabilities. We view the results as one step closer to SIGY treating life-threatening inflammatory conditions are precipitated by cytokine storm syndrome such as COVID-19, sepsis, etc.

The Details: SIGY reported the ability of the adsorbent components incorporated within Sigyn Therapy to address viral pathogens, including COVID-19. The result of exposure to Sigyn’s adsorbent components reduced the presence of SARS-CoV-2 pseudo-typed lentivirus by 68.8% from plasma. This model was utilized to study antiviral drugs development to treat COVID-19 and to assess the efficacy of vaccines against COVID-19 variants.

What This Means: Results from earlier in vitro studies validated the capability of its therapy to address a broad spectrum of inflammatory targets. These new results validate viral depletion in combination with pro-inflammatory cytokine elimination as a promising strategy to mitigate virus-induced cytokine storms.

Higher Value In the Offing? We believe that the FDA may be on a path to establish inflammatory cytokine reduction as a clinical endpoint to ameliorate cytokine storms that are induced by viral infections. This thesis is bolstered by a number of current clinical trials seeking to demonstrate the treatment of COVID-19 and other, virus-induced cytokine storm or cytokine release syndrome conditions. If this occurs, and SIGY could leverage this endpoint in a successful clinical trial, it could dramatically change the SIGY’s future value.

LOOKING AHEAD

Leveraging its multiple in vitro study results, the Company is poised to file an Investigational Device Exemption (IDE) with the FDA later this year. We believe that SIGY is not just poised to be awarded a potential Breakthrough Device designation in its category by the FDA in the coming year for key indications. Our thesis remains that SIGY could eventually be the first company to advance a medical device to treat Cytokine Storm Syndrome as its own categorical indication. Therefore, the aforementioned life-threatening conditions such as sepsis and COVID-19 could come under the CSS condition, offering clinicians a new weapon to fight this difficult to treat disorder. In the meantime, much of our focus is on the use of Sigyn Therapy to treat sepsis, given its large unmet need, with no approved therapy, despite the best efforts of dozens of firms. Moreover, if cleared just for sepsis, this incredibly lucrative event would be a boon to the company and its investors.

Looking ahead, if SIGY is awarded Breakthrough Device designation we believe the Company could be viewed as attractive M&A target by Tier 1 medical device players. Our confidence is rooted in our belief that the Company’s leadership is second to none in this therapeutic category. The CEO has led a NASDAQ-listed device company and co-authored submissions that resulted in two FDA Breakthrough Device awards. Plus, the co-founders oversaw the development of three devices that were approved by the FDA to treat COVID-19.

Our six-twelve-month price target for SIGY is $9.00, more than 4x its recent closing price. This target reflects the value of prospective milestone achievements as the Company transitions from a development stage company to a clinical stage firm. It is affirmed by using a discounted potential value of revenue generated as an FDA-approved Breakthrough Device and potential treatment for sepsis alone.

Senior Analyst: Robert Goldman

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This Opportunity Research report was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile and may offer greater upside. Goldman Small Cap Research was compensated by the Company in the amount of $7500 for research report and research update production and distribution. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.